Mayzent (Siponimod) Onboarding of Secondary Progressive Multiple Sclerosis (SPMS) Patients With MSGo
Completed
- Conditions
- Secondary Progressive Multiple Sclerosis
- Registration Number
- NCT05826028
- Lead Sponsor
- Novartis Pharmaceuticals
- Brief Summary
This study was a retrospective, non-interventional, longitudinal, descriptive study. This study did not have a key underlying hypothesis, rather it was designed to explore the onboarding and adherence of SPMS patients in Australia to Mayzent (siponimod) treatment.
Initiating siponimod involves pre-screen tests, including a CYP2C9 genotype test to determine siponimod maintenance dosing, and patients underwent a 6-day titration prior to maintenance. The MSGo platform was developed to support onboarding. It is an integrated digital platform that functions as a patient support service.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 368
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Average time for siponimod onboarding Up to 168 days
- Secondary Outcome Measures
Name Time Method Time to siponimod onboarding in pre-specified sub-groups Up to 168 days Percentage of patients who adhered to the titration protocol Up to 168 days Time on maintenance therapy Up to 168 days
Trial Locations
- Locations (1)
Novartis Investigational Site
🇦🇺St Leonards, New South Wales, Australia